CERT Certara

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences

RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:

  • BofA Securities 2025 Healthcare Conference

    Date and Time: Tuesday, May 13 at 3:40 p.m. PT
  • William Blair 45th Annual Growth Stock Conference

    Date and Time: Wednesday, June 4 at 12:40 p.m. CT

Live webcasts for each of the conferences will be available on Certara’s investor relations website at and will be available for replay for at least 90 days thereafter.

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.

Investor Relations Contact:

David Deuchler

Gilmartin Group

Media Contact:

Alyssa Horowitz



EN
29/04/2025

Underlying

CERTCertara

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Certara

 PRESS RELEASE
Free
CERT CERTARA

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: BofA Securities 2025 Healthcare ConferenceDate and Time: Tuesday, May 13 at 3:40 p.m. PT William Blair 45th Annual Growth Stock ConferenceDate and Time: Wednesday, June 4 at 12:40 p.m. CT Live webcasts for each of the conferences will be available on Certara’s investor relations website at and will be availa...

April 29, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 44.22
ANTM ANTHEM INC.
BKD Brookdale Senio... ... (+30)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

ANTM ANTHEM INC.
BKD BROOKDALE SENIOR LIVING INC.
STRL STERLING CONSTRUCTION COMPANY INC.
SLP SIMULATIONS PLUS
MKTX MARKETAXESS HOLDINGS INC.
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
HII HUMANA INC.
HCA HUNTINGTON INGALLS INDUSTRIES INC.
GD HCA HEALTHCARE INC
DLTR GENERAL DYNAMICS CORPORATION
DG DOLLAR TREE INC.
CVGW DOLLAR GENERAL CORPORATION
CNC CALAVO GROWERS INC.
CL CENTENE CORPORATION
CACI COLGATE-PALMOLIVE COMPANY
FDP CACI INTERNATIONAL INC CLASS A
SJW FRESH DEL MONTE PRODUCE INC.
LKO SJW GROUP
FIZZ LAKES OIL N.L.
CELH NATIONAL BEVERAGE CORP.
PAGS CELSIUS HOLDINGS INC.
STNE PAGSEGURO DIGITAL LTD
LHX STONECO
CERT L3HARRIS TECHNOLOGIES INC
MASS CERTARA
CTGO 908 DEVICES
NTST CONTANGO ORE INC.
YOU NETSTREIT CORP
HUM CLEAR SECURE INC
HAMILTON U.S. MID-CAP FINANCIALS ETF
04/17/25 April 17, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developer...

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its ™ solution designed to help biopharmaceutical companies lead the transition ignited by the The Roadmap marks a pivotal moment in drug development. Companies that act now...

April 14, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Reports Preliminary First Quarter 2025 Financial Results; Anno...

Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization Reiterates Full-Year 2025 GuidanceArsenal Capital Partners agrees to a one-year lock-up RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced expected revenue and bookings for the first quarter of 2025 based upon a preliminary review of first quarter results. Additionally, the company announced that its Board of Directors has authorized a stock repurchase program under which ...

April 14, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceut...

Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities Updates strengthen Certara’s position as a leader of PBPK modeling in drug development to advance regulatory decision-making RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the for physiologically-based pharmacokinetic (PBPK) modeling. Simcyp PBPK models describe and predict the behavior of drugs in different body tissues. The latest version includes numero...

April 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch